About the 2nd Annual IOBDLI Forum
The 2nd Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding & investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online One-2-One meeting system with dedicated meeting facilities to make the event more transactional.
2016 Programme will feature sessions on:
Confirmed Keynotes Include: “Driving Advancement in Cancer Immunotherapy” by Sophie Kornowski-Bonnet, Head of Roche Partnering, F. Hoffmann-La Roche AG "Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and prospects for Cures" - Abstract by James Allison, Chairman, Department of Immunology, Director, Immunology Platform, MD Anderson Cancer Center “CAR and TCR-engineered T-cells for the Treatment of Hematologic Malignancies and Solid Tumors” by Jeff Wiezorek, Senior Vice President, Clinical Development, Kite Pharma, Inc. "From the clinic to the lab: Investigating immune responses to immune checkpoint therapies" - Abstract by Padmanee Sharma, Scientific Director, Immunotherapy Platform, Professor, Department of Genitourinary Medical Oncology Professor, Department of Immunology, The University of Texas MD Anderson Cancer Center Confirmed Speakers & Chairs Include:
Presenting Opportunities:
Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed 10 or 20 minute presentations, also available as live-stream or recorded and edited. Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The Chicago forum provides the additional interaction with the academic/scientific and patient advocacy communities. Confirmed Presenters for 2016 Include:
To view company profiles please click HERE. Sponsorship and Exhibition:
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market. Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events. To learn more about presenting, exhibition or sponsorship opportunities, please contact: Silvia Kar on +44 203 463 4890 or by email: Silvia. For information about the last year's forum including topics, speakers, attending investors and more - click HERE |
Silver Sponsor:
Supported by:
Pharma Licensing Groups in 2016:
Financial / Advisory / Investors in 2016:
Alpha Bronze
Altius Strategy Consulting Amorchem Aquilo Capital Management Aurgalys Biotech Alliances International, Inc. BTIG, LLC Calamos Investments Cantor Fitzgerald Chardan Capital Markets, LLC Cowen and Company Dawson James Securities, Inc. Deca Ventures EcoR1 Capital, LLC Edison Group Enso Ventures F1BioVentures FBR & Co. GreenPeptide Co., Ltd. H.C. Wainwright & Co., LLC Healthy Assets Jefferies, LLC JP Morgan Katan Family Office Laidlaw & Company Loncar Investment, LLC Mediqventures MedPro Investors, LLC Merchant Liquidity Fund, LP MPM Capital New Leaf Venture Partners Nextech Invest Ltd. Noble Life Science Partners Oppenheimer & Co., Inc. Oslo Life Science Advisors Oxford Bioscience Partners QVT Financial LP Sante Ventures SMR Consulting GmbH Stifel Financial Corp. SunTrust Robinson Humphrey Torreya EM TVM Capital Versant Ventures Vertex Healthcare Ventures VI Partners AG Yorkville Advisors, LLC |